High materiality8/10
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS initiated coverage on Harmony with a Buy rating and $56 price target. Wakix sales reached $172.8 million in Q2 2024, growing 29% year-over-year. The patient count on Wakix increased to approximately 6,550 as of June 30, 2024. UBS projects a 19% sales CAGR for Harmony, higher than consensus at 16%. Recent acquisition of Epygenix adds to Harmony's pipeline potential and market reach.
- UBS initiated coverage on Harmony with a Buy rating and $56 price target.
- Wakix sales reached $172.8 million in Q2 2024, growing 29% year-over-year.
- The patient count on Wakix increased to approximately 6,550 as of June 30, 2024.
- UBS projects a 19% sales CAGR for Harmony, higher than consensus at 16%.
- Recent acquisition of Epygenix adds to Harmony's pipeline potential and market reach.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.